Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095

[11] Nidal R(2013)Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer Clin Cancer Res Off J Am Assoc Cancer Res 19 5182-91

[12] Eisenberger MA(2015)Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study EJNMMI Res 5 114-13

[13] Afshar-Oromieh A(2016)177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy J Nucl Med Off Publ Soc Nucl Med 57 1006-6

[14] Avtzi E(2016)PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617 J Nucl Med Off Publ Soc Nucl Med 57 1170-91

[15] Giesel FL(2016)Systemic radioligand therapy with (177)Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer J Urol 196 382-8

[16] Holland-Letz T(2016)Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer Clin Nucl Med 41 522-92

[17] Linhart HG(2014)Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy Eur J Nucl Med Mol Imaging 41 1280-30

[18] Eder M(2013)Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer Eur J Cancer Oxf Engl 49 3821-3

[19] Kratochwil C(2016)Metastatic prostate cancer with restored hormone-response after radioligand therapy with 177Lu-PSMA-617 Clin Nucl Med 41 572-53

[20] Afshar-Oromieh A(2016)Radioimmunotherapy of metastatic prostate cancer with 177Lu-DOTAhuJ591 anti prostate specific membrane antigen specific monoclonal antibody Curr Radiopharm 9 44-51

[11] Nidal R(2013)Phase II study of lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer Clin Cancer Res Off J Am Assoc Cancer Res 19 5182-91

[12] Eisenberger MA(2015)Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study EJNMMI Res 5 114-13

[13] Afshar-Oromieh A(2016)177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy J Nucl Med Off Publ Soc Nucl Med 57 1006-6

[14] Avtzi E(2016)PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with 177Lu-labeled PSMA-617 J Nucl Med Off Publ Soc Nucl Med 57 1170-91

[15] Giesel FL(2016)Systemic radioligand therapy with (177)Lu labeled prostate specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer J Urol 196 382-8

[16] Holland-Letz T(2016)Radioligand therapy with 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer Clin Nucl Med 41 522-92

[17] Linhart HG(2014)Radiation dosimetry and first therapy results with a (124)I/ (131)I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy Eur J Nucl Med Mol Imaging 41 1280-30

[18] Eder M(2013)Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer Eur J Cancer Oxf Engl 49 3821-3

[19] Kratochwil C(2016)Metastatic prostate cancer with restored hormone-response after radioligand therapy with 177Lu-PSMA-617 Clin Nucl Med 41 572-53

[20] Afshar-Oromieh A(2016)Radioimmunotherapy of metastatic prostate cancer with 177Lu-DOTAhuJ591 anti prostate specific membrane antigen specific monoclonal antibody Curr Radiopharm 9 44-51